First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Also received tentative approval for 137 mg
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subscribe To Our Newsletter & Stay Updated
